Colin Kirby

Co-Chair, Technology Industry Group
New York

I’m fortunate to work alongside the companies that are changing the world we live in.

Over the course of his career, Colin Kirby has advised founders and investors on hundreds of formation, financing and exit transactions. By taking the time to understand the strategic business objectives of his clients, Colin is able to apply tactical and forward-thinking guidance in a clear, concise and responsive manner.

While Colin’s practice focuses on the representation of growth-oriented companies and venture capital funds, he also works with investment funds and broker-dealers to facilitate innovative liquidity solutions for equity holders in later-stage growth companies.


  • Duke University School of Law, LL.M., Entrepreneurship, 2011
  • Notre Dame Law School, J.D., cum laude, 2010
  • University of California Santa Barbara, B.A., Political Science, International Relations, 2004

Bar and Court Admissions

  • New York
  • California


  • Industry-leading real estate purchasing platform, Avenue One Holdings, in Series Seed, Series A, and Series B financing transactions, the most recent of which resulted in a $50 million equity investment, led by a global investment leader
  • Brokerage platform Think Alpha Securities and its affiliate entities in various capital-raising and corporate transactions
  • Shift5, an OT cybersecurity company that defends military platforms and critical transportation systems from cyberattacks, in its $50 million Series B financing, led by Insight Partners, its $20 million Series A funding led by 645 Ventures, its convertible note financing and its $2.5 million seed financing led by Squadra Ventures
  • The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF), a leading manufacturer of cannabis products, in the acquisition of Green Roads worth up to $60 million
  • ZWI Therapeutics, Inc., a pharmaceutical company, in its $10 million Series A financing led by Co-Win Healthcare and Sherpa Healthcare
  • Prothelia, a company working to develop a therapeutic treatment for muscular dystrophy, in its Series A financing with participation from HealthCap, OrbiMed Private Investments, Novo Holdings and Venrock
  • Beacon Platform, a fintech company, in its $20 million Series B financing 
  • Satellite Biosciences, a developer of first-in-class, implantable satellite organs as living therapeutic solutions for serious diseases, in a Series Seed Preferred Stock Financing co-led by Polaris, Lightspeed and a Moon